AXIMOTCPharmaceutical PreparationsFiscal year ends December 31

AXIM BIOTECHNOLOGIES, INC.

Financials through Q2 FY2024, quarter ended Jun 30, 2024Last filing: 10-Q on Aug 19, 2024

$0.00+0.00 (+2.00%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

AXIM BIOTECHNOLOGIES, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Revenue	0.04	0.01	0.06	0	0.80	0.20	0.05	0.05	0.05	0	0.02	0.04	0.01
Cost of Revenue	–	–	–	0	0	0.01	0.04	0.15	0.05	0	–	–	–
Gross Profit	–	–	–	0	0	0.19	0.00	-0.11	0.00	0	–	–	–
Research & Development	0.13	0.15	0.28	0.43	0	2.06	1.35	0.24	0.57	0	–	–	–
Selling, General & Admin	2.24	4.08	5.67	–	–	–	–	3.41	9.48	0.51	–	–	–
General & Administrative	–	–	5.67	4.51	3.11	3.16	1.80	3.41	–	–	–	–	–
Operating Expenses	2.79	4.66	14	4.95	3.11	5.22	3.15	3.65	10	0.51	0.06	0.06	0.01
Operating Income	-2.75	-4.65	-14	-4.95	-3.11	-5.04	-3.15	-3.76	-10	-0.51	–	–	–
Interest Expense	0.14	0.26	0.14	0.23	0.22	0.46	0.32	0.28	0.04	0.03	–	–	–
Interest & Investment Income	0	0.00	0.00	0.00	–	0	0.00	0	–	–	–	–	–
Other Non-Operating Income	5.31	1.59	2.05	1.34	0.14	-1.72	-1.02	-2.05	0.04	0.03	–	–	–
Asset Impairment Charges	–	–	5.97	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	0	0.11	0.27	0	–	–	–	–	–	–	–
Legal Settlements	0.96	0	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	-8.06	-6.24	-16	-6.29	-2.97	-6.75	-4.17	-5.81	-10	-0.54	–	–	–
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	–	–	–
Income from Continuing Operations	0	0	-16	-6.29	-2.97	–	–	–	-10	-0.54	-0.06	–	–
Income from Discontinued Operations	–	0	-0.01	-0.12	-3.48	–	–	–	0	-0.04	-0.03	–	–
Net Income incl. Noncontrolling Interests	-8.06	-6.24	16	-6.41	-6.45	-6.75	-4.17	-5.81	-10	-0.58	-0.09	–	–
Net Income	-8.06	-6.24	-16	-6.41	-6.45	-6.75	-4.17	-5.81	-10	-0.58	-0.09	-0.01	0.00
Preferred Dividends	–	–	–	–	–	–	–	-1.48	0	–	–	–	–
Net Income to Common	–	-6.24	-16	-6.41	-6.45	-6.75	-4.17	-7.28	–	–	–	–	–
EPS (Basic)(per share)	-0.04	-0.04	0.12	-0.06	-0.10	-0.12	-0.08	-0.17	-0.27	-0.02	0.00	–	0.00
EPS (Diluted)(per share)	-0.04	-0.04	0.12	-0.06	-0.10	-0.12	-0.08	-0.17	-0.27	-0.02	0.00	–	0.00
Shares Outstanding (Basic, Weighted)(shares)	–	–	–	110	62	57	53	42	37	33	33	33	23
Shares Outstanding (Diluted, Weighted)(shares)	–	–	–	110	62	57	53	42	37	33	33	33	23
EBITDA	-2.32	-4.23	-12	-4.93	–	–	–	-3.76	-10	-0.51	–	–	–
Non-Interest Expense	0	0.18	–	–	–	–	–	0.21	0	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2024

Profitability, TTM

Gross margin: –
Operating margin: -2490.3%
Net margin: -4452.1%
Return on equity, FY2023: 129.1%

Financial strength

Current ratio: 0.00
Debt to equity: -0.02
Debt to assets: 5.0%
Cash to current liabilities: 0.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –